Intocell Overview

  • Founded
  • 2015
  • Status
  • Private
  • Latest Deal Type
  • Series B
  • Investors
  • 3

Intocell General Information


Developer of biotechnology platform designed to develop antibody-drug conjugate. The company's platform focus on the development and commercialization of novel ADC through comprising scaffold moiety, ligands, toxins, linkers and conjugation methods, enabling doctors to treat patients with diseases of unmet medical needs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 101, Sinildong-ro
  • Daejeon, Daedeok-gu
  • South Korea
+82 000-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Intocell Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series B) Completed Generating Revenue
5. Grant 30-Nov-2016 Completed Generating Revenue
4. Early Stage VC 27-Sep-2016 Completed Generating Revenue
3. Early Stage VC (Series A) 30-Jan-2016 Completed Generating Revenue
2. Grant 31-Dec-2015 Completed Startup
1. Early Stage VC 29-Apr-2015 Completed Startup
To view Intocell’s complete valuation and funding history, request access »

Intocell Executive Team (2)

Name Title Board Seat Contact Info
Tae Park Ph.D Chief Executive Officer
Yosup Rew Chief Technology Officer
To view Intocell’s complete executive team members history, request access »

Intocell Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Atinum Investment Venture Capital Minority 000 0000 000000 0
Stonebridge Capital Venture Capital Minority 000 0000 000000 0
Partners Investment Venture Capital Minority 000 0000 000000 0
To view Intocell’s complete investors history, request access »